Jahan A. Rahman

Nov 26, 2024 | cell.com | Kevin Scott |Hiroyuki Kojima |Nathalie Ropek |Charles Warren |Tiffany Zhang |Simon Hogg | +9 more

Keywordscovalent immunomodulatorsactivity-based protein profilinginterleukin-2-inducible T-cell kinasealternative splicingsplicing factor 3b subunit 1Get full text accessLog in, subscribe or purchase for full access. References1. Lynch, K.W.Consequences of regulated pre-mRNA splicing in the immune systemNat. Rev. Immunol. 2004; 4:931-9402. Martinez, N.M. ∙ Pan, Q. ∙ Cole, B.S. ... Alternative splicing networks regulated by signaling in human T cellsRNA. 2012; 18:1029-10403. Pan, Q. ∙ Shai, O.

Nov 15, 2024 | nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024. In the version of this article initially published, there were two typographical errors in the SS (Sezary syndrome) row in the Arm A section of Table 3. The PRR (partial response rate) for both all patients and at MTD only should have been shown as “50 (2)” instead of “29 (2)” and “40 (2)”, respectively. The errors do not affect the conclusions of the study.

Jun 17, 2024 | nature.com | Steven Horwitz |Ajit J Nirmal |Jahan A. Rahman |Ran Xu |Esther N. Drill |David Fisher | +7 more

AbstractPI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor duvelisib in T cell lymphomas (TCLs) that was associated with inflammatory adverse events.